...
huma-img

Humacyte Inc, Common Stock

HUMA

NSQ

$4.244

+$0.14

(3.41%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$527.54M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
669.66K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.47
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$2.48 L
$9.97 H
$4.244

About Humacyte Inc, Common Stock

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameHUMASectorS&P500
1-Week Return-15.11%-2.28%-0.57%
1-Month Return-23.22%-3.98%1.2%
3-Month Return-27.3%-9.71%7.56%
6-Month Return-43.06%-3.39%11.44%
1-Year Return40.89%3.69%28.47%
3-Year Return-59.29%3.78%29.51%
5-Year Return-57.6%39.76%90.64%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue6.19M1.49M1.26M1.56M-[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":24.1,"profit":true},{"date":"2021-12-31","value":20.41,"profit":true},{"date":"2022-12-31","value":25.29,"profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Cost of Revenue75.60M8.43M49.00K8.26M76.55M[{"date":"2019-12-31","value":98.76,"profit":true},{"date":"2020-12-31","value":11.02,"profit":true},{"date":"2021-12-31","value":0.06,"profit":true},{"date":"2022-12-31","value":10.78,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit(69.42M)(6.94M)1.21M(6.69M)(76.55M)[{"date":"2019-12-31","value":-5717.96,"profit":false},{"date":"2020-12-31","value":-571.75,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-551.07,"profit":false},{"date":"2023-12-31","value":-6305.6,"profit":false}]
Gross Margin(1121.97%)(465.53%)96.12%(427.48%)-[{"date":"2019-12-31","value":-1167.25,"profit":false},{"date":"2020-12-31","value":-484.32,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-444.73,"profit":false},{"date":"2023-12-31","value":"-","profit":true}]
Operating Expenses16.27M64.60M81.21M84.58M23.50M[{"date":"2019-12-31","value":19.24,"profit":true},{"date":"2020-12-31","value":76.38,"profit":true},{"date":"2021-12-31","value":96.02,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":27.78,"profit":true}]
Operating Income(85.69M)(64.60M)(81.21M)(84.58M)(100.05M)[{"date":"2019-12-31","value":-8569100000,"profit":false},{"date":"2020-12-31","value":-6460000000,"profit":false},{"date":"2021-12-31","value":-8120800000,"profit":false},{"date":"2022-12-31","value":-8457800000,"profit":false},{"date":"2023-12-31","value":-10004700000,"profit":false}]
Total Non-Operating Income/Expense-(3.85M)50.40M69.04M(11.50M)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-5.57,"profit":false},{"date":"2021-12-31","value":73,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-16.66,"profit":false}]
Pre-Tax Income(85.42M)(66.52M)(26.48M)(11.96M)(110.78M)[{"date":"2019-12-31","value":-8542200000,"profit":false},{"date":"2020-12-31","value":-6652400000,"profit":false},{"date":"2021-12-31","value":-2647700000,"profit":false},{"date":"2022-12-31","value":-1196500000,"profit":false},{"date":"2023-12-31","value":-11077600000,"profit":false}]
Income Taxes-2.20M(64.01M)(76.18M)3.11M[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":70.87,"profit":true},{"date":"2021-12-31","value":-2060.28,"profit":false},{"date":"2022-12-31","value":-2452.01,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Income After Taxes-(68.73M)37.54M64.22M(113.88M)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-107.02,"profit":false},{"date":"2021-12-31","value":58.45,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-177.34,"profit":false}]
Income From Continuous Operations-(66.52M)(26.48M)(11.96M)(89.39M)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-6652400000,"profit":false},{"date":"2021-12-31","value":-2647700000,"profit":false},{"date":"2022-12-31","value":-1196500000,"profit":false},{"date":"2023-12-31","value":-8939000000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(85.42M)(68.73M)37.54M64.22M(110.78M)[{"date":"2019-12-31","value":-133.02,"profit":false},{"date":"2020-12-31","value":-107.02,"profit":false},{"date":"2021-12-31","value":58.45,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-172.5,"profit":false}]
EPS (Diluted)-(0.01)(1.27)(0.13)(1.07)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-1,"profit":false},{"date":"2021-12-31","value":-127,"profit":false},{"date":"2022-12-31","value":-13,"profit":false},{"date":"2023-12-31","value":-107,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

HUMA
Cash Ratio 0.98
Current Ratio 1.10

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

HUMA
ROA (LTM) -53.23%
ROE (LTM) -850.81%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

HUMA
Debt Ratio Lower is generally better. Negative is bad. 1.56
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. -0.56

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

HUMA
Trailing PE NM
Forward PE NM
P/S (TTM) 153.91
P/B 30.28
Price/FCF NM
EV/R 0.00
EV/Ebitda 4.34

FAQs

What is Humacyte Inc share price today?

Humacyte Inc (HUMA) share price today is $4.244

Can Indians buy Humacyte Inc shares?

Yes, Indians can buy shares of Humacyte Inc (HUMA) on Vested. To buy Humacyte Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in HUMA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Humacyte Inc be purchased?

Yes, you can purchase fractional shares of Humacyte Inc (HUMA) via the Vested app. You can start investing in Humacyte Inc (HUMA) with a minimum investment of $1.

How to invest in Humacyte Inc shares from India?

You can invest in shares of Humacyte Inc (HUMA) via Vested in three simple steps:

  • Click on Sign Up or Invest in HUMA stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Humacyte Inc shares
What is Humacyte Inc 52-week high and low stock price?

The 52-week high price of Humacyte Inc (HUMA) is $9.97. The 52-week low price of Humacyte Inc (HUMA) is $2.48.

What is Humacyte Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Humacyte Inc (HUMA) is

What is Humacyte Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Humacyte Inc (HUMA) is 30.28

What is Humacyte Inc dividend yield?

The dividend yield of Humacyte Inc (HUMA) is 0.00%

What is the Market Cap of Humacyte Inc?

The market capitalization of Humacyte Inc (HUMA) is $527.54M

What is Humacyte Inc’s stock symbol?

The stock symbol (or ticker) of Humacyte Inc is HUMA

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top